Want to see IN:UNICHEMLAB full AI Analyst Report?
UNICHEMLAB Stock Chart & Stats
₹443.05
-₹12.85(-1.76%)
At close: 4:00 PM EST
₹443.05
-₹12.85(-1.76%)
Day’s Range― - ―
52-Week Range₹280.00 - ₹685.95
Previous CloseN/A
Volume14.19K
Average Volume (3M)11.59K
Market Cap
₹38.41B
Enterprise Value₹22.74K
Total Cash (Recent Filing)₹2.89B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)12.6
Beta1.25
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.34%
Share Statistics
EPS (TTM)43.29
Shares Outstanding70,405,754
10 Day Avg. Volume5,690
30 Day Avg. Volume11,587
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.76
Price to Sales (P/S)0.94
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a growing equity base provide financial resilience across the business cycle. This gives Unichem greater flexibility to sustain operations, support product development, and manage weaker periods without the elevated refinancing pressure associated with heavily debt-funded businesses.
Profitability RecoveryThe return to profitability demonstrates that earnings power has improved after the loss-making period. Although operating margins remain modest, sustained positive net income would strengthen internal funding capacity and provide a more stable base for future commercial and product investments.
Diversified Pharmaceutical PlatformExposure to branded medicines, generics, APIs, and multiple geographies creates several routes to revenue rather than dependence on one product or market. This breadth can support business durability by allowing strengths in one therapeutic area or region to offset pressure elsewhere.
Bears Say
Persistent Cash BurnWeak cash conversion is a durable financial constraint even after earnings recover. Persistent negative operating and free cash flow can increase reliance on balance-sheet flexibility or external funding, limit reinvestment choices, and raise execution risk if cash needs remain elevated.
Thin Operating MarginA thin operating margin leaves limited room to absorb pricing pressure, cost increases, or execution setbacks before core profitability is affected. It also means that the recent improvement in net earnings may not yet represent a robust or highly resilient operating earnings base.
Uneven Revenue And Earnings ProfileThe reversal from multi-year revenue expansion to contraction, combined with volatile gross margins and prior losses, indicates an uneven financial profile. This variability makes future earnings less predictable and complicates planning for durable growth, margins, and capital allocation.
Unichem Laboratories Limited News
UNICHEMLAB FAQ
What was Unichem Laboratories Limited’s price range in the past 12 months?
Unichem Laboratories Limited lowest stock price was ₹280.00 and its highest was ₹685.95 in the past 12 months.
What is Unichem Laboratories Limited’s market cap?
Unichem Laboratories Limited’s market cap is ₹38.41B.
When is Unichem Laboratories Limited’s upcoming earnings report date?
Unichem Laboratories Limited’s upcoming earnings report date is Nov 04, 2026 which is in 44 days.
How were Unichem Laboratories Limited’s earnings last quarter?
Unichem Laboratories Limited released its earnings results on Aug 11, 2026. The company reported ₹5.89 earnings per share for the quarter.
Is Unichem Laboratories Limited overvalued?
According to Wall Street analysts Unichem Laboratories Limited’s price is currently Overvalued.
Does Unichem Laboratories Limited pay dividends?
Unichem Laboratories Limited pays a Annually dividend of ₹4 which represents an annual dividend yield of 1.34%. See more information on Unichem Laboratories Limited dividends here
What is Unichem Laboratories Limited’s EPS estimate?
Unichem Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Unichem Laboratories Limited have?
Unichem Laboratories Limited has 70,405,754 shares outstanding.
What happened to Unichem Laboratories Limited’s price movement after its last earnings report?
Unichem Laboratories Limited reported an EPS of ₹5.89 in its last earnings report. Following the earnings report the stock price went up 13.062%.
Which hedge fund is a major shareholder of Unichem Laboratories Limited?
Currently, no hedge funds are holding shares in IN:UNICHEMLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Unichem Laboratories Limited
Unichem Laboratories Limited is an international pharmaceutical company engaged in the development, manufacturing, and commercialization of a wide array of medicinal products. The firm's portfolio features finished pharmaceutical formulations designed to treat numerous health conditions, including those related to gastroenterology, cardiovascular health, diabetes, mental health, neurological disorders, bacterial and other infectious diseases, and pain relief. Beyond these formulations, Unichem also provides active pharmaceutical ingredients (APIs) and offers contract manufacturing solutions. This enterprise was established in 1944 and operates from its corporate headquarters in Mumbai, India.
Technical Analysis
Gufic Biosciences Limited
―
Hikal Limited
―
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
Windlas Biotech Ltd.
―